378 related articles for article (PubMed ID: 34700256)
1. Virtual screening using docking and molecular dynamics of cannabinoid analogs against CB
Aviz-Amador A; Contreras-Puentes N; Mercado-Camargo J
Comput Biol Chem; 2021 Dec; 95():107590. PubMed ID: 34700256
[TBL] [Abstract][Full Text] [Related]
2. Prediction of the Binding Affinities and Selectivity for CB1 and CB2 Ligands Using Homology Modeling, Molecular Docking, Molecular Dynamics Simulations, and MM-PBSA Binding Free Energy Calculations.
Ji B; Liu S; He X; Man VH; Xie XQ; Wang J
ACS Chem Neurosci; 2020 Apr; 11(8):1139-1158. PubMed ID: 32196303
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Ligand Efficacy of Cannabinoid Receptor 1 (CB1) using Molecular Dynamics Simulations.
Jung SW; Cho AE; Yu W
Sci Rep; 2018 Sep; 8(1):13787. PubMed ID: 30213978
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
5. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.
Tham M; Yilmaz O; Alaverdashvili M; Kelly MEM; Denovan-Wright EM; Laprairie RB
Br J Pharmacol; 2019 May; 176(10):1455-1469. PubMed ID: 29981240
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol inhibits sucrose self-administration by CB1 and CB2 receptor mechanisms in rodents.
Bi GH; Galaj E; He Y; Xi ZX
Addict Biol; 2020 Jul; 25(4):e12783. PubMed ID: 31215752
[TBL] [Abstract][Full Text] [Related]
7. 7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands.
Penthala NR; Shoeib A; Dachavaram SS; Cabanlong CV; Yang J; Zhan CG; Prather PL; Crooks PA
Bioorg Med Chem Lett; 2020 Nov; 30(22):127501. PubMed ID: 32882418
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
[TBL] [Abstract][Full Text] [Related]
9. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
10. Crystal Structure of the Human Cannabinoid Receptor CB2.
Li X; Hua T; Vemuri K; Ho JH; Wu Y; Wu L; Popov P; Benchama O; Zvonok N; Locke K; Qu L; Han GW; Iyer MR; Cinar R; Coffey NJ; Wang J; Wu M; Katritch V; Zhao S; Kunos G; Bohn LM; Makriyannis A; Stevens RC; Liu ZJ
Cell; 2019 Jan; 176(3):459-467.e13. PubMed ID: 30639103
[TBL] [Abstract][Full Text] [Related]
11. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
12. Computational investigation on the binding modes of Rimonabant analogs with CB1 and CB2.
Liu C; Yuan C; Wu P; Zhu C; Fang H; Wang L; Fu W
Chem Biol Drug Des; 2018 Sep; 92(3):1699-1707. PubMed ID: 29797785
[TBL] [Abstract][Full Text] [Related]
13. Identification of CB1/CB2 ligands from Zanthoxylum bungeanum.
Dossou KS; Devkota KP; Morton C; Egan JM; Lu G; Beutler JA; Moaddel R
J Nat Prod; 2013 Nov; 76(11):2060-4. PubMed ID: 24175626
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
15. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG
Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387
[TBL] [Abstract][Full Text] [Related]
16. Preface.
Methods Enzymol; 2017; 593():xvii-xxiv. PubMed ID: 28750818
[No Abstract] [Full Text] [Related]
17. Cannabidiol skews biased agonism at cannabinoid CB
Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
[TBL] [Abstract][Full Text] [Related]
18. Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.
McPartland JM; Duncan M; Di Marzo V; Pertwee RG
Br J Pharmacol; 2015 Feb; 172(3):737-53. PubMed ID: 25257544
[TBL] [Abstract][Full Text] [Related]
19. Comparative molecular dynamics simulations of the potent synthetic classical cannabinoid ligand AMG3 in solution and at binding site of the CB1 and CB2 receptors.
Durdagi S; Reis H; Papadopoulos MG; Mavromoustakos T
Bioorg Med Chem; 2008 Aug; 16(15):7377-87. PubMed ID: 18595717
[TBL] [Abstract][Full Text] [Related]
20. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice.
Myers AM; Siegele PB; Foss JD; Tuma RF; Ward SJ
Br J Pharmacol; 2019 May; 176(10):1552-1567. PubMed ID: 29338068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]